News
1d
Zacks Investment Research on MSNCVS Up on Medicare Advantage Strength: Is It a Buy Before Q2 Earnings?CVS Health Corporation CVS is gaining investor attention as the stock trends higher ahead of its second-quarter earnings ...
While major pharmacy benefit management reform was stripped out of the Big Beautiful Bill, a bipartisan group of ...
This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...
U.S. Reps. Raja Krishnamoorthi, D-Ill., and Earl “Buddy” Carter, R-Ga., along with nine other representatives, introduced a ...
CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...
Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...
CVS Caremark has removed coverage of Zepbound, a GLP-1 weight-loss drug, citing pricing concerns and shifting payer dynamics ...
Last month, CVS Caremark announced that it had struck a deal to make Novo's Wegovy its primary weight loss drug starting in the second half of the year, which would mean coverage for Lilly's ...
Pharmacy benefit manager CVS Caremark decided to replace Zepbound with Wegovy for use in weight loss starting July 1, despite Zepbound users having more weight loss success.
Cigna's announcement follows CVS Caremark designating Wegovy as its preferred weight loss drug last month.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results